BTK and B-cell non-Hodgkin lymphoma: Targeted degradation of BTK, a crucial target in R/R B-cell lymphomas, by PROTACs, has been explored in three completed clinical trials, which were presented at the American Society of Hematology Meeting in 2023 [262].